Beta blockers are associated with lower all-cause mortality among HFpEF patients.
Joseph IbrahimCarly FabrizioAhmet SezerFloyd ThomaBrenden BoyleSuresh R MulukutlaJessica H HustonMarc A SimonGavin W HickeyPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2024)
In a large single-center retrospective registry, BB use was associated with lower mortality in HFpEF patients with a recent decompensated HF hospitalization. The mortality benefit persisted in those treated with spironolactone or ACEi/ARBs, and in those with AF. This provocative data further highlights the uncertainty of the benefit of BB use in this cohort and calls for re-consideration of BB withdrawal, especially in those tolerating it well, without conclusive, large, and randomized trials showing lack of benefit or harm.
Keyphrases
- growth factor
- ejection fraction
- end stage renal disease
- newly diagnosed
- cardiovascular events
- heart failure
- chronic kidney disease
- recombinant human
- risk factors
- peritoneal dialysis
- prognostic factors
- electronic health record
- cross sectional
- coronary artery disease
- angiotensin converting enzyme
- patient reported
- angiotensin ii
- hepatitis b virus
- deep learning
- liver failure